Form 4: Codexis Director H. Stewart Parker Acquires Over 40,000 Shares in RSU Grant

Codexis, Inc. Director H. Stewart Parker reported the acquisition of 40,983 shares of common stock through a restricted stock unit grant, increasing his total beneficial ownership to 143,583 shares.

Summary

• H. Stewart Parker, a Director of Codexis, Inc. (CDXS), acquired 40,983 shares of common stock.
• The acquisition occurred on June 10, 2025.
• These shares were acquired at a price of $0, indicating a grant, likely restricted stock units (RSUs).
• Following this transaction, H. Stewart Parker's total beneficial ownership in Codexis, Inc. stands at 143,583 shares.
• The restricted stock units are subject to a vesting schedule: they vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on the director's continued service to the Company on such vesting date.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even if through a grant, generally indicates continued commitment and alignment with the company's future, which is a positive signal. There are no negative financial implications or red flags in this standard regulatory filing.

Positives

• Director H. Stewart Parker increased his beneficial ownership in Codexis, Inc. by 40,983 shares, demonstrating continued alignment with shareholder interests.
• The acquisition was a grant of restricted stock units, a common form of equity compensation that incentivizes long-term commitment and performance.

Risks

• The vesting of the restricted stock units is subject to the director's continued service to the company, meaning the shares are not immediately liquid and could be forfeited if service ceases before vesting.

Future Outlook

The vesting schedule for the granted restricted stock units indicates a future milestone, with shares vesting on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on continued service.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, common practice across various industries, including biotechnology, to align executive and director incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• Equity grants, particularly Restricted Stock Units (RSUs) with service-based vesting, are a standard component of director compensation packages across publicly traded companies, including those in the biotechnology sector like Codexis.
• While specific grant sizes vary based on company size, performance, and individual roles, the mechanism of granting RSUs at a $0 price is consistent with typical non-cash compensation practices.
• No specific comparable companies or projects are mentioned in this regulatory filing to allow for a direct quantitative comparison of the grant size.

Stakeholder Impact

• Shareholders: The increase in director ownership aligns the director's interests with shareholders, potentially signaling confidence in the company's future.

Next Steps

• The restricted stock units will vest on the earlier of June 10, 2026 (first anniversary of grant) or the date of the next annual stockholder meeting, subject to continued service.

Key Dates

Keywords

Codexis, CDXS, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSU, Director Compensation, Equity Grant